Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06976606 · ClinicalTrials.gov registry record

A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM

A clinical trial of Arrhythmogenic Cardiomyopathy and PKP2-ACM, sponsored by Lexeo Therapeutics.

Recruiting
Registry status
40
Enrollment target
6
Study locations

NCT06976606: Recruiting study of Arrhythmogenic Cardiomyopathy and PKP2-ACM, sponsored by Lexeo Therapeutics.

NCT06976606 is a study of Arrhythmogenic Cardiomyopathy and PKP2-ACM that is actively recruiting participants, run by Lexeo Therapeutics. The registered enrollment target is 40 participants. The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06976606, a study of Arrhythmogenic Cardiomyopathy and PKP2-ACM, is actively recruiting participants, sponsored by Lexeo Therapeutics.

RECRUITING
Registry status
40 participants
Enrollment target
6
Study locations

Study Summary

An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.

Primary Outcome

Change from baseline

Study Locations (6)

Maryland

  • Johns Hopkins University - Baltimore
  • Northshore University Healthsystem Research Institute - Columbia

Michigan

  • University of Michigan - Ann Arbor
  • Henry Ford Hospital - Detroit

California

  • Leland Stanford Junior University - Redwood City

New York

  • University of Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-01-23
Est. Completion 2027-09
Lexeo Therapeutics

6 total trials

What NCT06976606 shows while recruiting

NCT06976606 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.

The record links to 3 conditions, with Arrhythmogenic Cardiomyopathy appearing as the primary indexed condition, and to 0 interventions.

NCT06976606 lists 6 locations in 4 states (Maryland, Michigan, California).

Frequently Asked Questions

What is clinical trial NCT06976606 about?

NCT06976606 is a clinical study titled "A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM". An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.

What is the current status of trial NCT06976606?

This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2024-01-23. Estimated completion is 2027-09.

What conditions does trial NCT06976606 study?

This clinical trial studies the following conditions: Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC.

Who is sponsoring clinical trial NCT06976606?

This trial is sponsored by Lexeo Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06976606 being conducted?

This trial has 6 study locations across California, Maryland, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Arrhythmogenic Cardiomyopathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06976606, the US trial registry maintained by the National Library of Medicine. NCT06976606 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.